Moderna Begins Phase 1 Trial For Ebola VaccineModerna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prevent Bundibugyo ebolavirus disease, for which no licensed vaccines currently exist.The study is being conducted in Canada as part of a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million to support preclinical testing and the Phase 1 trial.The partnership also includes funding for the scaled manufacturing of additional clinical trial doses alongside early-stage development.The strategy is designed to accelerate the start of larger Phase 2 and Phase 3 studies if Phase 1 results are positive.Under its agreement with CEPI, Moderna has committed to making at least 500,000 doses available at access pricing for timely distribution to low- and middle-income countries.Analyst OutlookThe stock carries a consensus Hold rating with an average analyst price forecast of $52.11. Recent analyst actions include:
Citigroup: Neutral; raised price forecast to $60 on Aug. 3.
Goldman Sachs: Neutral; raised price forecast to $67 on July 21.
Morgan Stanley: Equal-Weight; raised price forecast to $39 on July 8.
